Wednesday, 20 Nov 2019

PsA/SpA

Datesort ascending Type Title Save
11 Nov 2019 Social RT @DrPetryna: Do you feel comfortable combining apremilast with biologics in refractory/difficult to treat PsA patients ?
11 Nov 2019 ACR Video Gender Differences in Ankylosing Spondylitis: Dr. Torkell Juulsgaard
11 Nov 2019 Social RT @uptoTate: Small study suggests subclinical inflammation detected by MRI in joints of hand in PsA patients in MDA. Abst #1171 #ACR19 #AC…
11 Nov 2019 Social RT @synovialjoints: Does anti-TNF treatment halt radiographc progression in ankylosing spondylitis? #ACR19 @RheumNow Vote here
11 Nov 2019 Social RT @DrKanikaMonga: What a pleasant surprise to be included in the #axSpA poster tour today — my research - showing an association with wor…
10 Nov 2019 Social RT @DrKanikaMonga: Woo hoo! @rheum_cat and her poster on CV disease risk in aXSpA abstr #622 #ACR19 https://t.co/eaDyCKZs5J
07 Nov 2019 News Most Psoriatics Go on Biologics
05 Nov 2019 News Year in Review - Psoriatic Arthritis 2019
04 Nov 2019 Social Cancer Risk with psoriasis? Metanalysis of 58 studies shows that PSO is associated with an 18-22% increased risk of all cancers, highest w/ severe PSO. Increased risk of colon, laryngeal, liver, lymphoma/NHL, esophageal, oral cavity & pancreatic CA https://t.co/HYOej7mrbQ
04 Nov 2019 News EXCEED Study: Cosentyx Equals Humira in Psoriatic Arthritis
01 Nov 2019 News Rinvoq (upadacitinib) Effective in Psoriatic Arthritis
01 Nov 2019 Social Data on 14 261 PsA patients (from 11 European registries) startin TNFi therapy - shows that half (56%) were in DAS28 remission and 53% were ACR20 responders after 6 months, and 3/4 were still on TNFi at 1 year https://t.co/RIHVjyJ7bn
01 Nov 2019 Social Study of 1810 AS pts from British registry on ankylosing spondylitis (BSRBR-AS) finds lower quality of life in AS is due to disease activity, depression, sleep disturbance, activity impairment, fibromyalgia, Widespread Pain, and tobacco smoking https://t.co/m0oG156CgY
31 Oct 2019 Social Claims analysis of psoriasis & PsA treated with inhibitors of TNF , IL-17 (SEC, IXE) or IL12/23 (UST) (2015-18) shows 2% of biologic starts had serious infections. SIE rates equal for TNFi & IL-17i; but were lower for IL-12/23 vs TNFi (HR=0.59; 0.39 -.90) https://t.co/YbNmEe19tS
31 Oct 2019 Social Swedish study of comorbidities compared 982 Psoriatic arthritis patients to the general population, finding PsA pts had higher rates of Obesity (BMI ≥ 30) (28.6% vs 16.3%), HTN (40.3% vs 24.1%) & diabetes (10.5% vs 6.2%). https://t.co/fFQ1almeJR
29 Oct 2019 Social Study of 238 PsA patients starting a biologic shows that comparing those w/ comorbid FM vs without, PsA pts with FM had lower biologic survival (50% vs 74%) and PsA-FM unlikely to achieve remission (3.4% at 3mos and 0% at 6 months). https://t.co/29RAIEtGZA
28 Oct 2019 Social Metanalysis of 373 citations and 14 studies was unable to prove a protective X-ray benefit of TNF inhibitors in patients with axial spondyloarthritis. https://t.co/CSffpEEmHo
27 Oct 2019 Social Mediterranean diet study of 211 Psoriatic Arthritis patients. 27% had MetSyndr. Moderate adherence 66%. Disease activity (DAPSA, HAQ) was inversely correlated with diet adherence. The most active PsA had the lowest adherence https://t.co/2Yf22zEH2o
24 Oct 2019 Social Observational study of the meditteranean diet on 211 Psoriatic Arthritis patients. 27% had MetSyndr. Moderate adherence 66%. Disease activity (DAPSA, HAQ) was inversely correlated with diet adherence. The most active PsA had the lowest adherence https://t.co/2Yf22zEH2o
23 Oct 2019 Social Toronto longitudinal study of 1061 Psoriatic arthritis patients finds 343 had liver test abnormalities (prevalence 32%) w/ incidence rate of 39/1000 patient-years. Liver abnormalities were detected after a follow up duration of 8.3 ±7.8 years. https://t.co/FmAIJsPANu